Treating Alcohol Use In Older Adults With Depression

This study has been completed.

First Received: July 3, 2001 Last Updated: January 20, 2009 History of Changes

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018824

Purpose

The purpose of this study is to test the efficacy combining a treatment for depression with a treatment for alcohol dependence.

Condition	Intervention	Phase
Alcoholism Depression	Drug: NALTREXONE	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Official Title:	The Treatment of Late Life Major Depression Complication by Alcohol

Resource links provided by NLM:

MedlinePlus related topics: Alcoholism Depression

Drug Information available for: Naltrexone Naltrexone hydrochloride

U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	October 1999
Estimated Study Completion Date:	October 2002

Detailed Description:

This study aims to study 80 patients with comorbid alcohol dependence and a depressive syndrome. After appropriate detoxification, patients are started on either naltrexone 50 mg or placebo. After one week, sertraline is added in an open label fashion. It is hypothesized that those patients receiving combination therapy will last 3 months with follow-up tracking lasting 1 year.

Eligibility

Ages Eligible for Study:	55 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Age > 55
Current depressive syndrome
Current alcohol dependence
No psychosis
No opioid or cocaine abuse or dependence

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018824

Locations

United States, Pennsylvania
Philadelphia Vamc
PHILADELPHIA, Pennsylvania, United States, 19104

Sponsors and Collaborators

Department of Veterans Affairs

More Information

No publications provided

Study ID Numbers:	MHBS-009-98S
Study First Received:	July 3, 2001
Last Updated:	January 20, 2009
ClinicalTrials.gov Identifier:	NCT00018824 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Depression
Narcotic Antagonists
Disorders of Environmental Origin
Narcotics
Depressive Disorder, Major
Depressive Disorder
Alcohol Drinking
Behavioral Symptoms

Mental Disorders
Alcoholism
Naltrexone
Substance-Related Disorders
Mood Disorders
Alcohol-Related Disorders
Peripheral Nervous System Agents
Ethanol

Additional relevant MeSH terms:

Depression
Narcotic Antagonists
Physiological Effects of Drugs
Disorders of Environmental Origin
Depressive Disorder
Pharmacologic Actions
Behavioral Symptoms
Sensory System Agents
Mental Disorders

Therapeutic Uses
Alcoholism
Naltrexone
Substance-Related Disorders
Mood Disorders
Alcohol-Related Disorders
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 02, 2009